Overview

Health care cost to society has risen to levels which are no longer sustainable.

This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology.

The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in “pure-play” digital health companies, which are typically small to mid-sized.

The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

The exchange rate risk between USD and EUR is not hedged.

Benefits

Offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry.

The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.

Risks

UBS Thematic Funds invest in equities and may therefore be subject to high fluctuations in value. As these UBS Funds pursue an active to very active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on specifict themes and trends may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk). This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class. Sustainability risks are environmental, social or governance events or conditions that can have a material negative effect on the return, depending on the relevant sector, industry and company exposure. Sustainability risk: the risk arising from any environmental, social or governance events or conditions that, were they to occur, could cause a material negative impact on the value of the investment.

Features

Product category
UBS Thematic Funds
Product domicile
Luxembourg
Portfolio management
UBS SA国际传谋 (Americas) LLC, New York
Fund management
UBS SA国际传谋 (Europe) S.A., Luxembourg
Custodian bank
UBS Europe SE, Luxembourg Branch
Representative for products established under foreign law
UBS Europe SE, sucursal en España
Day of inception
September 14, 2018
Currency of account
EUR
Close of financial year
May 31
SFDR Classification
Art.8
Issue / redemption
daily
Maturity
Open end
Ongoing costs p.a.
1.86% p.a.
Management fee
1.60% p.a.
Minimum investment
n.a.
Reference Index / Benchmark
MSCI AC World (NR) in EUR
ISIN
LU1877633989
Bloomberg Ticker
CSGDHAE LX
Reuters Id
43558975X.CHE

Performance and Prices

Percentage growth

as of April 23, 2026
Cumulative
EUR(%)
YTD
1M
3M
6M
1Y
2Y -2.16
3Y
5Y -45.75
ø p.a.5Y -11.51

Current data

Net asset value 23.04.2026 EUR 105.90
High - last 12 months 28.11.2025 EUR 119.74
Low - last 12 months 30.03.2026 EUR 99.38
Last distribution 17.07.2025 EUR 0.00
Assets of the unit class in mn 23.04.2026 EUR 4.57
Total product assets in mn 23.04.2026 EUR 465.42

Structures

By the 10 largest positions (in %, as of March 31, 2026)

 
 
Intuitive Surgical Inc 3.57
Guardant Health Inc 3.53
Arrowhead Pharmaceuticals Inc 3.20
Alcon AG 3.13
Kymera Therapeutics Inc 3.12
Denali Therapeutics Inc 3.11
IRhythm Holdings Inc 3.05
Koninklijke Philips NV 2.99
CG oncology Inc 2.97
Ionis Pharmaceuticals Inc 2.78

Fees

Ongoing costs p.a.
1.86%
Flat fee
n.a.
Management fee p.a.
1.60%
Max. issuing commission
5.00%
Max. redemption commission
0.00%
Distribution fee
(see info)

Distributions

From
01-Nov-2020
To
01-Nov-2021
Date of distribution
Pay date
Cps no.
Currency
Distribution
15.07.2025 17.07.2025 - EUR 0.00

Sales Authorisations

Market
Sales authorisations status
Australia
Institutional Only*
Austria
Registered
Bahrain
Institutional Only*
Belgium
Registered
Costa Rica
Institutional Only*
France
Registered
Germany
Registered
Italy
Registered
Liechtenstein
Registered
Luxembourg
Registered
Netherlands
Registered
Portugal
Registered
Saudi Arabia
Institutional Only*
Singapore
Institutional Only*
Spain
Registered
Switzerland
Registered

Literature

Brochures
Document type
Document Language
Fact Sheet
Manager Commentary
Fact Sheet - UBS Thematic Funds
Agreement / Prospectus
Document type
Document Language
Prospectus
Key Information Document
Past performance
Previous performance scenario
Statutes / Management regulations
Annual and semi-annual report (accounting on May 31)
Document type
Document Language
Annual report
Semi-annual report
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.